NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization498.23 mln
Float6.01 mln
Earnings Date08/07/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
80.00
Transformational upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.04
Debt-free
ROE
-36.99
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Neurogene Inc. is a New York-based company founded in 2018 that focuses on developing treatments for rare brain and nervous system disorders. Its two lead programs are currently in early-stage clinical trials ? one targeting Rett syndrome and another aimed at CLN5 Batten disease, both of which are serious conditions with very limited treatment options. The company works under licensing agreements with several academic and research institutions to support its drug development efforts.
